Denali Therapeutics Inc (NASDAQ:DNLI)’s Trend Up, Especially After Decreased Shorts

May 25, 2018 - By Vivian Park

The stock of Denali Therapeutics Inc (NASDAQ:DNLI) registered a decrease of 3.58% in short interest. DNLI’s total short interest was 4.78 million shares in May as published by FINRA. Its down 3.58% from 4.96M shares, reported previously. With 118,800 shares average volume, it will take short sellers 40 days to cover their DNLI’s short positions. The short interest to Denali Therapeutics Inc’s float is 96.87%.

The stock decreased 1.77% or $0.36 during the last trading session, reaching $19.98. About 109,039 shares traded. Denali Therapeutics Inc. (NASDAQ:DNLI) has 0.00% since May 25, 2017 and is . It has underperformed by 11.55% the S&P500.

Denali Therapeutics Inc., a biopharmaceutical company, engages in discovering and developing therapeutics for neurodegenerative diseases in the United States. The company has market cap of $1.89 billion. The company's lead LRRK2 product candidates includes the DNL201, a small molecule inhibitor that is in Phase I clinical trials, as well as DNL151, a small molecule inhibitor, which is in preclinical development stage for the treatment of Parkinson's disease. It currently has negative earnings. It is also developing therapeutics for the treatment of Parkinson's, dementia with Lewy bodies, and multiple system atrophy; amyotrophic lateral sclerosis; and mucopolysaccharidosis type II patients.

More important recent Denali Therapeutics Inc. (NASDAQ:DNLI) news were published by: which released: “Denali Therapeutics Reports First Quarter 2018 Financial Results” on May 11, 2018, also published article titled: “‘Bursting at the seams,’ this high-profile Peninsula biotech company is moving to a bigger home”, published: “Pushing Preclinical: Wave Of Early-Stage Biotech IPOs Tests Investor Risk Appetite” on May 09, 2018. More interesting news about Denali Therapeutics Inc. (NASDAQ:DNLI) was released by: and their article: “Why Big Pharma is finally discovering the Bay Area” with publication date: May 23, 2018.

Denali Therapeutics Inc. (NASDAQ:DNLI) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.